IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0079323.html
   My bibliography  Save this article

Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial

Author

Listed:
  • Matthew B Laurens
  • Mahamadou A Thera
  • Drissa Coulibaly
  • Amed Ouattara
  • Abdoulaye K Kone
  • Ando B Guindo
  • Karim Traore
  • Idrissa Traore
  • Bourema Kouriba
  • Dapa A Diallo
  • Issa Diarra
  • Modibo Daou
  • Amagana Dolo
  • Youssouf Tolo
  • Mahamadou S Sissoko
  • Amadou Niangaly
  • Mady Sissoko
  • Shannon Takala-Harrison
  • Kirsten E Lyke
  • Yukun Wu
  • William C Blackwelder
  • Olivier Godeaux
  • Johan Vekemans
  • Marie-Claude Dubois
  • W Ripley Ballou
  • Joe Cohen
  • Tina Dube
  • Lorraine Soisson
  • Carter L Diggs
  • Brent House
  • Jason W Bennett
  • David E Lanar
  • Sheetij Dutta
  • D Gray Heppner
  • Christopher V Plowe
  • Ogobara K Doumbo

Abstract

Background: The FMP2.1/AS02A candidate malaria vaccine was tested in a Phase 2 study in Mali. Based on results from the first eight months of follow-up, the vaccine appeared well-tolerated and immunogenic. It had no significant efficacy based on the primary endpoint, clinical malaria, but marginal efficacy against clinical malaria in secondary analyses, and high allele-specific efficacy. Extended follow-up was conducted to evaluate extended safety, immunogenicity and efficacy. Methods: A randomized, double-blinded trial of safety, immunogenicity and efficacy of the candidate Plasmodium falciparum apical membrane antigen 1 (AMA1) vaccine FMP2.1/AS02A was conducted in Bandiagara, Mali. Children aged 1–6 years were randomized in a 1∶1 ratio to receive FMP2.1/AS02A or control rabies vaccine on days 0, 30 and 60. Using active and passive surveillance, clinical malaria and adverse events as well as antibodies against P. falciparum AMA1 were monitored for 24 months after the first vaccination, spanning two malaria seasons. Findings: 400 children were enrolled. Serious adverse events occurred in nine participants in the FMP2.1/AS02A group and three in the control group; none was considered related to study vaccination. After two years, anti-AMA1 immune responses remained significantly higher in the FMP2.1/AS02A group than in the control group. For the entire 24-month follow-up period, vaccine efficacy was 7.6% (p = 0.51) against first clinical malaria episodes and 9.9% (p = 0.19) against all malaria episodes. For the final 16-month follow-up period, vaccine efficacy was 0.9% (p = 0.98) against all malaria episodes. Allele-specific efficacy seen in the first malaria season did not extend into the second season of follow-up. Interpretation: Allele-specific vaccine efficacy was not sustained in the second malaria season, despite continued high levels of anti-AMA1 antibodies. This study presents an opportunity to evaluate correlates of partial protection against clinical malaria that waned during the second malaria season. Trial Registration: Clinicaltrials.gov NCT00460525 NCT00460525

Suggested Citation

  • Matthew B Laurens & Mahamadou A Thera & Drissa Coulibaly & Amed Ouattara & Abdoulaye K Kone & Ando B Guindo & Karim Traore & Idrissa Traore & Bourema Kouriba & Dapa A Diallo & Issa Diarra & Modibo Dao, 2013. "Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-9, November.
    • Handle: RePEc:plo:pone00:0079323
    DOI: 10.1371/journal.pone.0079323
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0079323
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0079323&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0079323?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Mahamadou A Thera & Ogobara K Doumbo & Drissa Coulibaly & Dapa A Diallo & Abdoulaye K Kone & Ando B Guindo & Karim Traore & Alassane Dicko & Issaka Sagara & Mahamadou S Sissoko & Mounirou Baby & Mady , 2008. "Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial," PLOS ONE, Public Library of Science, vol. 3(1), pages 1-11, January.
    2. Mahamadou A Thera & Ogobara K Doumbo & Drissa Coulibaly & Matthew B Laurens & Abdoulaye K Kone & Ando B Guindo & Karim Traore & Mady Sissoko & Dapa A Diallo & Issa Diarra & Bourema Kouriba & Modibo Da, 2010. "Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial," PLOS ONE, Public Library of Science, vol. 5(2), pages 1-11, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Mahamadou A Thera & Ogobara K Doumbo & Drissa Coulibaly & Matthew B Laurens & Abdoulaye K Kone & Ando B Guindo & Karim Traore & Mady Sissoko & Dapa A Diallo & Issa Diarra & Bourema Kouriba & Modibo Da, 2010. "Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial," PLOS ONE, Public Library of Science, vol. 5(2), pages 1-11, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0079323. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.